Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Depomed, Inc.
Depomed Completes Enrollment of Serada’s Full Phase 3 Clinical Program in Menopausal Hot Flashes
April 25th, 2009
Depomed, Inc. (NASDAQ:DEPO) announced that it has completed enrollment of Breeze 2, the second of two pivotal Phase 3 clinical trials of SeradaTM (formerly referred to as DM-5689) for the treatment of menopausal hot flashes. “I would like to thank all clinical investigators, patients, and Depomed employees whose efforts allowed us to complete enrollment of our full Phase 3 clinical program for Serada. We are encouraged by the level of interest in a non-hormonal alternative treatment for menopausal hot flashes that we noticed during the recruitment of patients. This confirms that there is a significant unmet need existing in the marketplace. We look forward to the...
Source: Law & Health Weekly (2009-04-25)
|
